genedrive plc Cash Flow Conversion Efficiency
genedrive plc cash flow conversion efficiency. Based on the latest financial reports, genedrive plc (GDR) has a cash flow conversion efficiency ratio of -1.421x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-2.04 Million ≈ $-248.70 USD) by net assets (GBX1.44 Million ≈ $174.96 USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of genedrive plc (2006–2025)
Cash flow conversion efficiency of genedrive plc from 2006 to 2025. This chart illustrates how genedrive plc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View genedrive plc stock price for real-time trading data and today's change.
genedrive plc Cash Flow Conversion Ratio Explained
genedrive plc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
genedrive plc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of genedrive plc ranked by their cash flow conversion efficiency. Also see GDR company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Cadogan Petroleum plc
LSE:CAD
|
-0.008x |
|
Red Capital PLC
LSE:REDC
|
2.418x |
|
MagForce AG
STU:MF6
|
N/A |
|
Marlowe plc
LSE:MRL
|
0.184x |
|
Pod Point Group Holdings PLC
LSE:PODP
|
-1.031x |
|
LANEBURY GROWTH CAP.
F:L01
|
-0.024x |
|
One Media iP Group Plc
LSE:OMIP
|
0.048x |
|
FUSION FUEL GREEN CL.A
F:60P
|
N/A |
Annual Cash Flow Conversion Efficiency for genedrive plc (2006–2025)
The table below shows the annual cash flow conversion efficiency of genedrive plc from 2006 to 2025. Review genedrive plc free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | GBX1.44 Million ≈ $174.96 |
GBX-5.10 Million ≈ $-620.64 |
-3.547x | -404.51% |
| 2024-06-30 | GBX5.36 Million ≈ $652.04 |
GBX-3.77 Million ≈ $-458.46 |
-0.703x | +62.00% |
| 2023-06-30 | GBX2.04 Million ≈ $248.33 |
GBX-3.78 Million ≈ $-459.43 |
-1.850x | -125.18% |
| 2022-06-30 | GBX5.61 Million ≈ $682.70 |
GBX-4.61 Million ≈ $-560.90 |
-0.822x | +43.07% |
| 2021-06-30 | GBX3.59 Million ≈ $437.04 |
GBX-5.18 Million ≈ $-630.74 |
-1.443x | -227.33% |
| 2020-06-30 | GBX-3.34 Million ≈ $-406.62 |
GBX-3.79 Million ≈ $-460.89 |
1.133x | -22.43% |
| 2019-06-30 | GBX-2.48 Million ≈ $-301.50 |
GBX-3.62 Million ≈ $-440.57 |
1.461x | +39.82% |
| 2018-06-30 | GBX-2.44 Million ≈ $-296.51 |
GBX-2.55 Million ≈ $-309.90 |
1.045x | +295.77% |
| 2017-06-30 | GBX3.44 Million ≈ $418.67 |
GBX-1.84 Million ≈ $-223.51 |
-0.534x | +42.77% |
| 2016-06-30 | GBX3.75 Million ≈ $456.63 |
GBX-3.50 Million ≈ $-425.97 |
-0.933x | -169.33% |
| 2015-06-30 | GBX9.54 Million ≈ $1.16K |
GBX-3.31 Million ≈ $-402.24 |
-0.346x | -244.58% |
| 2014-06-30 | GBX10.86 Million ≈ $1.32K |
GBX-1.09 Million ≈ $-132.86 |
-0.101x | -97.99% |
| 2013-06-30 | GBX12.05 Million ≈ $1.47K |
GBX-612.00K ≈ $-74.46 |
-0.051x | -66.01% |
| 2012-06-30 | GBX8.86 Million ≈ $1.08K |
GBX-271.00K ≈ $-32.97 |
-0.031x | +72.95% |
| 2011-06-30 | GBX6.18 Million ≈ $752.17 |
GBX-699.00K ≈ $-85.05 |
-0.113x | +8.53% |
| 2010-06-30 | GBX5.78 Million ≈ $703.75 |
GBX-715.00K ≈ $-86.99 |
-0.124x | -118.01% |
| 2009-06-30 | GBX2.76 Million ≈ $335.81 |
GBX1.89 Million ≈ $230.45 |
0.686x | +256.66% |
| 2008-06-30 | GBX2.58 Million ≈ $314.15 |
GBX-1.13 Million ≈ $-137.61 |
-0.438x | -41.49% |
| 2007-06-30 | GBX2.60 Million ≈ $315.98 |
GBX-804.00K ≈ $-97.82 |
-0.310x | +61.17% |
| 2006-06-30 | GBX1.09 Million ≈ $133.23 |
GBX-873.00K ≈ $-106.22 |
-0.797x | -- |
About genedrive plc
genedrive plc engages in the design, development, and manufacture of molecular diagnostics testing equipment for use in genotyping, pathogen detection, infectious disease detection, and other clinical indications. The company provides Genedrive system, rapid nucleic acid thermocycler and fluorescence signal detection system for target discrimination used for qualitative in vitro molecular diagnos… Read more